share_log

Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $26

Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $26

Canaccord Genuity维持对Annovis Bio的买入,将目标股价下调至26美元
Benzinga ·  04/30 08:02

Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $36 to $26.

Canaccord Genuity分析师苏曼特·库尔卡尼维持安诺维斯生物(纽约证券交易所代码:ANVS)的买入并将目标股价从36美元下调至26美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发